Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946880 · ClinicalTrials.gov registry record · Phase 2
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT01946880 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 102 participants.
The verdict
NCT01946880, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.
Interventions
- DRUG Prednisone
- DRUG Mycophenolate Mofetil
- DRUG Hydroxychloroquine or Chloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-11-20 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946880
The ClinicalTrials.gov registry entry for NCT01946880 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT01946880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946880 about?
NCT01946880 is a clinical study titled "Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)". This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.
What is the current status of trial NCT01946880?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2013-11-20. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT01946880?
The interventions under investigation include: Prednisone (DRUG), Mycophenolate Mofetil (DRUG), Hydroxychloroquine or Chloroquine (DRUG).
Who is sponsoring clinical trial NCT01946880?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.